Free Trial

Prime Medicine (PRME) News Today

Prime Medicine logo
$1.29 +0.06 (+4.88%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.28 -0.01 (-1.09%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why is Prime Medicine Up Today?

Prime Medicine, Inc. (NYSE:PRME) shares are trading higher today after a mixed set of analyst updates. Upward revisions to near-term earnings forecasts from Chardan Capital and Wedbush have been partially offset by longer-term cuts and a rating downgrade from HC Wainwright, with other firms maintaining neutral views.

  • Chardan Capital raised its FY2025 EPS estimate to ($1.25) from ($1.39) and keeps a “Buy” rating with a $12.00 target
  • Wedbush boosted its Q3 2025 EPS forecast to ($0.32) from ($0.41), reiterating an “Outperform” rating and a $13.00 target
  • JPMorgan Chase & Co. reaffirmed its “Neutral” rating on PRME shares
  • JMP Securities set a $6.00 price target for Prime Medicine
  • HC Wainwright downgraded shares to “Neutral” from “Buy” and cut its FY2029 EPS forecast to ($0.85) from ($0.80)
Posted 1+ days agoAI Generated. May Contain Errors.

PRME Latest News

Prime Medicine, Inc. stock logo
Chardan Capital Raises Earnings Estimates for Prime Medicine
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Chardan Capital boosted their FY2025 earnings per share (EPS) estimates for shares of Prime Medicine in a note issued to investors on Tuesday, May 20th. Chardan Capital analyst G. Livshits now anticipates that the company will
FY2025 EPS Estimates for Prime Medicine Increased by Analyst
Prime Medicine, Inc. stock logo
HC Wainwright Lowers Earnings Estimates for Prime Medicine
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Investment analysts at HC Wainwright reduced their FY2029 earnings per share (EPS) estimates for Prime Medicine in a report released on Tuesday, May 20th. HC Wainwright analyst A. He now anticipates that the company will earn ($0.85) per share for
Prime Medicine FY2029 EPS Forecast Lowered by HC Wainwright
Prime Medicine, Inc. stock logo
Wedbush Has Bullish Estimate for Prime Medicine Q3 Earnings
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at Wedbush lifted their Q3 2025 earnings per share (EPS) estimates for shares of Prime Medicine in a report released on Monday, May 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per s
Prime Medicine, Inc. stock logo
Westwood Holdings Group Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)
Westwood Holdings Group Inc. lifted its stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 96.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 883,129 shares of the company's stock after purchasing an additional 433,653
What is Wedbush's Estimate for Prime Medicine Q3 Earnings?
Prime Medicine (NYSE:PRME) Stock Rating Lowered by HC Wainwright
Prime Medicine, Inc. stock logo
Prime Medicine (NYSE:PRME) Downgraded to "Neutral" Rating by HC Wainwright
HC Wainwright lowered shares of Prime Medicine from a "buy" rating to a "neutral" rating in a research note on Tuesday.
Prime Medicine, Inc. stock logo
Prime Medicine's (PRME) Neutral Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Prime Medicine in a report on Tuesday.
Prime Medicine, Inc. stock logo
Analysts Offer Predictions for Prime Medicine Q1 Earnings
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings per share estimates for Prime Medicine in a note issued to investors on Thursday, May 8th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.38) per share for th
Prime Medicine, Inc. stock logo
Prime Medicine, Inc. (NYSE:PRME) Given Average Recommendation of "Buy" by Analysts
Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rati
Prime Medicine, Inc. stock logo
T. Rowe Price Investment Management Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)
T. Rowe Price Investment Management Inc. lifted its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,977,828 shares of the company's stock af
Prime Medicine, Inc. stock logo
Prime Medicine, Inc. (NYSE:PRME) Shares Bought by Walleye Capital LLC
Walleye Capital LLC raised its holdings in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 272.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 403,739 shares of the company's stock af
Prime Medicine, Inc. stock logo
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Buy" by Analysts
Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has been given an average recommendation of "Buy" by the nine ratings firms that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The
Prime Medicine, Inc. stock logo
Wedbush Forecasts Prime Medicine FY2029 Earnings
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Wedbush issued their FY2029 earnings per share estimates for Prime Medicine in a report released on Tuesday, March 18th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($1.27) per share for the year. Wed
Prime Medicine, Inc. stock logo
Prime Medicine (NYSE:PRME) Stock Price Expected to Rise, Chardan Capital Analyst Says
Chardan Capital upped their target price on shares of Prime Medicine from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Thursday.
Prime Medicine price target raised to $16 from $15 at Chardan
Prime Medicine, Inc. stock logo
Prime Medicine's (PRME) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Prime Medicine in a research note on Wednesday.
Prime Medicine, Inc. stock logo
Prime Medicine's (PRME) "Outperform" Rating Reiterated at Wedbush
Wedbush restated an "outperform" rating and issued a $13.00 target price (up from $12.00) on shares of Prime Medicine in a research note on Tuesday.
Prime Medicine unveils program for treatment of AATD
Prime Medicine, Inc. stock logo
Chardan Capital Estimates Prime Medicine FY2025 Earnings
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Prime Medicine in a research report issued to clients and investors on Monday, March 10th. Chardan Capital analyst G. Livshits expects that the company will post earnings pe
Prime Medicine, Inc. stock logo
Prime Medicine (NYSE:PRME) Releases Quarterly Earnings Results
Prime Medicine (NYSE:PRME - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($1.65) earnings per share for the quarter.
Prime Medicine, Inc. stock logo
Q1 EPS Estimates for Prime Medicine Lifted by HC Wainwright
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Prime Medicine in a research note issued on Monday, March 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($
Get Prime Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.

PRME Media Mentions By Week

PRME Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PRME
News Sentiment

0.12

0.76

Average
Medical
News Sentiment

PRME News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PRME Articles
This Week

36

3

PRME Articles
Average Week

Get Prime Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSE:PRME) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners